

ongoing trials - trial from www.clinicaltrials.gov

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 - Phase 2 - Not yet recruiting

Code: NCT03969888

Year: 2019

Date: August 27, 2019

Author: AbbVie

Study design (if review, criteria of inclusion for studies)

Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment

Participants

Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

Interventions

Drug: ABBV-3067|Drug: Placebo ABBV-3067|Drug: ABBV-2222|Drug: Placebo ABBV-2222

Outcome measures

Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Absolute change in sweat chloride (SwCl)|Absolute change in forced vital capacity (FVC)|Absolute change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Relative change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in forced vital capacity (FVC)

<https://ClinicalTrials.gov/show/NCT03969888>

Keywords

Adult; Aminophenols; Anti-Bacterial Agents; CFTR Modulators; G551D-CFTR; Genetic Predisposition to Disease; pharmacological_intervention; Quinolones; VX-770; ivacaftor; GLPG2222; ABBV2222; GLPG3067; ABBV3067;